Brief: Sage Therapeutics Announces Topline Results From Phase 2 PRECEDENT Study Of Dalzanemdor (SAGE-718)
17/04/2024 12:56
April 17 (Reuters) - SAGE Therapeutics Inc SAGE.O :
* SAGE THERAPEUTICS ANNOUNCES TOPLINE RESULTS FROM PHASE 2
PRECEDENT STUDY OF DALZANEMDOR (SAGE-718) IN THE TREATMENT OF
MILD COGNITIVE IMPAIRMENT IN PARKINSON’S DISEASE
* SAGE THERAPEUTICS INC: DALZANEMDOR (SAGE-718) WAS
GENERALLY
WELL-TOLERATED AND THERE WERE NO NEW SAFETY SIGNALS OBSERVED
* SAGE THERAPEUTICS INC: TOPLINE DATA READOUTS FROM PHASE 2
STUDIES IN HUNTINGTON'S DISEASE AND ALZHEIMER'S DISEASE ARE
EXPECTED LATER THIS YEAR
* SAGE THERAPEUTICS: SAGE-718 DID NOT SHOW STATISTICALLY
SIGNIFICANT DIFFERENCES VERSUS PLACEBO ON PRIMARY ENDPOINT
Source text for Eikon: ID:nBw8zBTKja
Further company coverage: SAGE.O
Recent news on Sage Therapeutics
See all newsBrief: Supernus Pharmaceuticals Completes Acquisition Of Sage Therapeutics
Sage Therapeutics Inc Reports Results For The Quarter Ended June 30: Earnings Summary
SAGE Therapeutics Q2 revenue rises sequentially
Brief: Supernus Pharmaceuticals Announces Expiration Of Hart-Scott-Rodino Waiting Period For Sage Therapeutics Tender Offer
Sage Therapeutics Inc Expected To Post A Loss Of 95 Cents A Share: Earnings Preview